News
BPTSY
1.380
NaN%
--
Weekly Report: what happened at BPTSY last week (0112-0116)?
Weekly Report · 1d ago
Weekly Report: what happened at BPTSY last week (0105-0109)?
Weekly Report · 01/12 09:32
Weekly Report: what happened at BPTSY last week (1229-0102)?
Weekly Report · 01/05 09:30
Weekly Report: what happened at BPTSY last week (1222-1226)?
Weekly Report · 12/29/2025 09:29
Weekly Report: what happened at BPTSY last week (1215-1219)?
Weekly Report · 12/22/2025 09:29
Weekly Report: what happened at BPTSY last week (1208-1212)?
Weekly Report · 12/15/2025 09:32
Weekly Report: what happened at BPTSY last week (1201-1205)?
Weekly Report · 12/08/2025 09:32
Weekly Report: what happened at BPTSY last week (1124-1128)?
Weekly Report · 12/01/2025 09:30
Weekly Report: what happened at BPTSY last week (1117-1121)?
Weekly Report · 11/24/2025 09:32
Weekly Report: what happened at BPTSY last week (1110-1114)?
Weekly Report · 11/17/2025 09:33
Biophytis Announces Approval of Resolutions at General Meeting
TipRanks · 11/14/2025 14:15
Weekly Report: what happened at BPTSY last week (1103-1107)?
Weekly Report · 11/10/2025 09:31
Weekly Report: what happened at BPTSY last week (1027-1031)?
Weekly Report · 11/03/2025 09:31
Biophytis Releases Interim Financial Report for H1 2025
TipRanks · 10/31/2025 13:48
Weekly Report: what happened at BPTSY last week (1020-1024)?
Weekly Report · 10/27/2025 09:33
Weekly Report: what happened at BPTSY last week (1013-1017)?
Weekly Report · 10/20/2025 09:32
Biophytis Partners with Asian Consortium for Landmark Sarcopenia Trial
Barchart · 10/15/2025 05:38
Weekly Report: what happened at BPTSY last week (1006-1010)?
Weekly Report · 10/13/2025 09:32
Weekly Report: what happened at BPTSY last week (0929-1003)?
Weekly Report · 10/06/2025 09:31
More
Webull provides a variety of real-time BPTSY stock news. You can receive the latest news about Biophytis Sa through multiple platforms. This information may help you make smarter investment decisions.
About BPTSY
Biophytis SA, formerly Institut Biophytis Sas is a France-based company engaged in the healthcare industry. The Company is a biotechnology entity specialized in the development of drug candidates to treat ageing diseases. Its two programs relate to sarcopenia (loss of muscle functionality) and Age Related Macular Degeneration (ARMD). Biophytis SA is engaged in the clinical and regulatory development of its drug candidates, such as Sarconeos (BIO101) and Macuneos (BIO201), simultaneously in the United States and domestic market.